Our strategy
We are a focused biopharma company. We prevent and treat disease with vaccines, specialty and general medicines. We focus on the science of the immune system and advanced technologies, investing in four core therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology. Our Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems.
Our long-term priorities
We’re uniting science, technology and talent to make a difference in more people’s lives. We don’t just want to find new, better medicines and vaccines. By harnessing our science and technology, we have an opportunity to prevent disease in the first place, as well as change the course of a disease – helping to prevent or slow progression of an illness and limit long-term complications. Our broad portfolio and pipeline continues to strengthen, with key milestones across our core therapeutic areas in 2023. Strategic partnerships are critical to opening up new avenues of discovery. We have important collaborations, including with the University of Oxford on neurodegenerative diseases, Kings College London on cancer treatment and 23andMe on genetics and genomics.
-
Vaccines and medicines in the pipeline
71 -
Assets in phase III/registration
18 -
Major approvals in 2023
4
We’re confident in our future. Our bold ambitions for patients are reflected in our upgraded growth outlooks to 2026 and 2031. This means more GSK vaccines and medicines, including innovative new products, will reach more people who need them than ever before.
Creating value for patients, shareholders, society
-
Packs of medicines and doses of vaccines delivered in 2023
2.3bn -
Per share dividend in 2023
58p -
Corporate income tax paid; in addition we pay duties, levies, transactional and employment taxes
£1.3bn
Being a responsible business means getting ahead of disease together in the right way. That’s why ESG is embedded in our strategy and supports our sustainable performance and long-term growth. We therefore need to consider ESG impacts across everything we do, from the lab to the patient. We have identified six ESG focus areas that address what is most material to our business and the issues that matter to our stakeholders. These focus areas are access to healthcare, global health and health security, environment, diversity, equity and inclusion, ethical standards, product governance.
Our culture
Culture at GSK is something we all own. It powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive. Our culture of being ambitious for patients, accountable for impact and doing the right thing is the foundation for how, together, we’ll deliver for patients, shareholders and GSK people.
Our Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.
The Code
Meet our Outstanding people
WHAT’S YOUR ANGLE?
Our film series brings together our people from teams across the world to discuss the issues that matter across the themes of diversity, equity and inclusion, and explore their different perspectives.